Literature DB >> 7547635

Molecular analysis of genetic changes in ependymomas.

E K Bijlsma1, A M Voesten, E H Bijleveld, D Troost, A Westerveld, P Mérel, G Thomas, T J Hulsebos.   

Abstract

Ependymomas are glial cell-derived tumors. They are, in contrast to other gliomas (astrocytomas, oligodendrogliomas, and oligoastrocytomas), ill-defined with respect to the genes and chromosomal segments important in their tumorigenesis. In this study, we extensively screened 17 ependymomas for genetic changes characteristic of other gliomas. Allelic loss was detected on chromosome arm 22q in three tumors; on chromosome 10 in two tumors; on chromosome arm 17p in two tumors; and on chromosome arms 6q, 9p, 13q, and 19q, each in one tumor. No allelic losses were found on chromosome arms 1p and 16q. None of the tumors had EGFR gene amplification. In each case, the chromosomal segment affected by the deletion included the region known to harbor a tumor suppressor gene important in glioma tumorigenesis. We conclude that ependymomas resemble the other glial neoplasms with respect to type and location of the chromosomal changes involved. Given the relatively infrequent occurrence of these genetic changes, ependymomas should be considered genetically as low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547635     DOI: 10.1002/gcc.2870130407

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups.

Authors:  Y Hirose; K Aldape; A Bollen; C D James; D Brat; K Lamborn; M Berger; B G Feuerstein
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 4.  Application of advances in molecular biology to the treatment of brain tumors.

Authors:  H Takeshima; Y Sawamura; M R Gilbert
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

5.  Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.

Authors:  M J T Verstegen; D Troost S Leenstra; H Ijlst-Keizers; D A Bosch
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Molecular cytogenetic studies of pediatric ependymomas.

Authors:  D L Kramer; A H Parmiter; L B Rorke; L N Sutton; J A Biegel
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

7.  A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor.

Authors:  Takashi Yokota; Takayuki Tachizawa; Koichi Fukino; Akira Teramoto; Jun Kouno; Koshi Matsumoto; Mitsuru Emi
Journal:  J Hum Genet       Date:  2003-10-18       Impact factor: 3.172

Review 8.  The genetic and epigenetic basis of ependymoma.

Authors:  Stephen C Mack; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2009-06-18       Impact factor: 1.475

9.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

10.  Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation.

Authors:  A C J Ammerlaan; M P W A Houben; C C Tijssen; P Wesseling; T J M Hulsebos
Journal:  Childs Nerv Syst       Date:  2008-01-31       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.